Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures

Lexaria Bioscience Corp (NASDAQ:LEXX) has commenced a new study to compare the effectiveness of Epidiolex to DehydraTECH-cannabidiol (CBD) for reducing seizure activity.
Related Link: Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients.
Epidiolex, developed by GW Pharmaceuticals plc, is the first and only FDA-approved CBD medication for seizures associated with two rare and severe forms of pediatric epilepsy.
The study is designed to investigate if DehydraTECH-CBD has similar or superior levels of efficacy in treating seizures as Epidiolex.
GW Pharmaceuticals is now sold by Jazz Pharmaceuticals Plc (NASDAQ:JAZZ).
Animal study EPIL-A21-1 has entered early-stage preparatory work, and results are expected by Q3 2022.
Also Read: GW Pharmaceuticals' Cannabidiol For Seizures Wins UK Approval.
Price Action: LEXX shares are up 1.32% at $6.27 during the market session on the last check Monday.

Insights